ClinicalTrials.gg
RecruitingNCT07145190Updated Aug 11, 2026

SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment

An observational study in Parkinson Disease, sponsored by Bial - Portela C S.A.. Recruiting at 12 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Bial - Portela C S.A. · Observational

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
90
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies in Parkinson Disease by Bial - Portela C S.A. — 1 open to participants now, 2 under way, none of them phase 3. Parkinson Disease · Bial - Portela C S.A..

Started
2025
with 1 other
Observational
3 of 60
1 open now
Registered
58th of 60
by date

Among the 60 studies in Parkinson Disease by Bial - Portela C S.A., this one is one of 2 that started in 2025, is one of 3 observational ones, and was the 58th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 60 studies in Parkinson Disease by Bial - Portela C S.A. is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Parkinson Disease by Bial - Portela C S.A., or all of them as a file.
02

Study summary

The purpose of the study is to generate real-world evidence data for the on-demand treatment with SL-APO, focusing on understanding its usage and titration practices including individual dose determination after dose-adjustment to ultimately understand their influence in patient satisfaction, treatment persistence, and the balance between effectiveness and safety. The data may help optimize titration approaches to better meet the patient's needs.

Read the detailed description

This study is a prospective, observational, real-word evidence study. It is a non-interventional study according to article 2(4) of the Clinical Trials Regulation. Visits are documented as they occur in the routine of the practice or PD clinic.

The medical evaluation that leads to a treatment plan for the patient is not part of this study. The treatment plan may not include SL-APO. This study protocol becomes relevant only after unbiased prescription of SL-APO. Under no circumstances will access to treatment be contingent upon participation in the study. No additional procedures or examinations are required besides the ones already performed per local medical practice.

Patients who will initiate SL-APO according to the SmPC are potential study patients. After the patient's consent to participate in the study, the study starts with the baseline visit at the site (dark blue icon). The tolerance and efficacy of 10 mg SL-APO is tested for a patient in the OFF-state. In case of an insufficient "ON"-response of the first 10 mg dose, dose finding continues with titration at home (light blue house). The Titration follow-up (FU) takes place during the dose finding phase preferably when the patient has reached the preferred dose. The Titration FU can take place as a call or on-site. If a patient is not in the optimal dose during the Titration FU, they will be called again, as per their practice routine. Note, the only data collected from the Titration FU is if the optimal dose according to the HCP has been reached (and the date of the call). Patients will keep a Patient Titration Diary from the baseline visit to the end of titration. The diary entries are started from the 2nd intake of SL-APO. This is regardless of whether the intake takes place at home or in the clinical environment. Patients will keep a Patient Maintenance Diary after the end of titration until the end of the study. For at least the first 7 days and a minimum of 10 intakes, the Patient Maintenance Diary is kept daily, followed by a weekly entry. At 3 and 6 months, FU visits take place at the site. The 6-month FU visit marks the end of the study. The Investigator will decide if patients should continue to be prescribed the maintenance dose after the end of the trial.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Kynmobi
  • SL-APO
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients experiencing OFF symptoms which cannot be managed by oral anti-PD medication. For clarification, patients who have previously been exposed to apomorphine can also be included in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient is ≥ 18 years of age.
  • The patient has a clinical diagnosis of idiopathic Parkinson's disease.
  • The patient will initiate SL-APO for the treatment of OFF episodes according to the SmPC.
  • The patient is not currently on titration or maintenance dose for SL-APO.
  • The patient has provided written to participate in this study.

Exclusion criteria

Exclusion Criteria:

  • The patient is participating in a clinical trial with an drug.
  • The patient has presented with dementia or evidence of cognitive decline as determined by the investigator.
  • The patient has a history of psychotic disorder.
  • The patient presents any other according to the SL-APO SmPC.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
90 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • SL-START

    SL-APO is available as a treatment initiation pack, containing two sublingual films of each strength (total of 30 films). The treatment initiation pack is usually used at the start of treatment to find an effective and tolerable dose. Depending on the patient response, not all doses in this pack may be needed.

    Drug: SL-APO

Interventions

  • DrugSL-APO

    Patients should start with a dose of 10 mg SL-APO. Dose initiation should occur when the patient is having an OFF episode. If the patient tolerates the 10 mg dose, and responds adequately (meaning satisfactory motor response within 30 minutes), the maintenance dose should be 10 mg. If the dose is tolerated but the response is insufficient, continue to titrate in 5 mg increments when the patient is having an OFF episode and assess response until an effective and tolerable dose is achieved, up to a maximum of 30 mg per dose and up to five times a day. If an "ON" response is achieved and if clinically warranted, consider the need to further up-titrate as tolerated to achieve a better "ON" response. The minimal interval between doses is 2 hours, with no more than one dose of SL-APO per OFF episode.

    Also known as: Kynmobi

06

What researchers measure

Primary outcomes

  1. Identify the most frequent dose used after dose-adjustment

    The purpose of the study is to generate real-world evidence data for the on-demand treatment with SLAPO, focusing on understanding its usage and titration practices including individual dose determination after dose-adjustment to ultimately understand their influence in patient satisfaction, treatment persistence, and the balance between effectiveness and safety. The data may help optimize titration approaches to better meet the patient's needs.

    Time frame: Up to 6 months

07

Study locations

10 of 12 sites recruiting
  • Charité - Universitätsmedizin Berlin - Sektion für Bewegungsstörungen und Neuromodulation
    Berlin, 10117, Germany
    Recruiting
  • Alexianer St. Joseph Berlin-Weißensee GmbH
    Berlin, 13088, Germany
    Suspended

    Not enrolling at this site.

  • Praxis für Neurologie
    Berlin, 15366, Germany
    Recruiting
  • Katholisches Klinikum Bochum gGmbH, Universitätsklinikum St.Josef-Hospital, Klinik für Neurologie
    Bochum, 44791, Germany
    Not yet recruiting
  • UNIVERSITÄTSKLINIKUM FREIBURG - Neurozentrum Klinik für Neurologie und Neurophysiologie im Neurozentrum
    Freiburg im Breisgau, D-79106, Germany
    Recruiting
    • Michel Rijntjes, Prof Dr med · Contact076127053570
  • Praxis für Neurologie und Psychiatrie
    Fulda, 36037, Germany
    Recruiting
  • Klinik am Tharandter Wald
    Hetzdorf, 09633, Germany
    Recruiting
  • Klinik für Neurologie und Neurologische Frührehabilitation
    Osnabrück, 49076, Germany
    Recruiting
  • Die Nerven Docs
    Siegen, 57072, Germany
    Recruiting
  • Neurologische Klinik Sorpesee
    Sundern, 59846, Germany
    Recruiting
  • Praxis für Neurologie und Geriatrie
    Ulm, 89073, Germany
    Recruiting
  • Neurologie am Funkerberg
    Wusterhausen, 15711, Germany
    Recruiting
    • Andreas Funke, Dr. med. · Contact01709095741
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Feb 2028, 30 months after the start.

Of 60 industry-sponsored observational studies under Parkinson Disease, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 30 months is below that.

Counting every sponsor, half of 439 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2025
First posted
Aug 28, 2025
StartActual
Aug 27, 2025
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07145190
Responsible party
Sponsor
First posted
Aug 28, 2025
Start date
Aug 27, 2025
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Aug 11, 2026

Study contacts

Ruben Arnelas
Contact
clinical.trials@bial.com
+351229866100
Jan Kassubek, Prof Dr med
principal investigator · Praxis für Neurologie und Geriatrie (Ulm)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion